Search research articles
Contact Us
Filters
Showing results (1-10 of 53) with videos related to
Page
of 6
Sort By:
Important Advances in Oncology
|
January 1, 1987
High-dose chemotherapy with bone marrow support for solid tumors
K Antman, J P Eder, E Frei
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2017
BET inhibitors: a novel epigenetic approach
D B Doroshow, J P Eder, P M LoRusso
Cancer Research
|
November 1, 1990
Phase I trial of escalating pentoxifylline dose with constant dose thiotepa
B J Dezube, J P Eder, A B Pardee
The Journal of Biological Chemistry
|
January 25, 1993
Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line
V T Chan, S W Ng, J P Eder, et al.
Cancer Research
|
January 15, 1991
A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity
J P Eder, C A Wheeler, B A Teicher, et al.
The Journal of Biological Chemistry
|
October 27, 1995
Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene
S W Ng, J P Eder, L E Schnipper, et al.
The Journal of Biological Chemistry
|
July 5, 1993
Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells
J P Eder, V T Chan, E Niemierko, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
Influence of scheduling on two-drug combinations of alkylating agents in vivo
B A Teicher, S A Holden, S M Jones, et al.
Cancer Treatment Reports
|
July 1, 1986
Pharmacokinetics and immediate effects of high-dose carmustine in man
W D Henner, W P Peters, J P Eder, et al.
The Journal of Clinical Investigation
|
May 1, 1987
Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model
J P Eder, B A Teicher, S A Holden, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 53) with videos related to
Sort By:
Page
of 6
Important Advances in Oncology
|
January 1, 1987
High-dose chemotherapy with bone marrow support for solid tumors
K Antman, J P Eder, E Frei
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2017
BET inhibitors: a novel epigenetic approach
D B Doroshow, J P Eder, P M LoRusso
Cancer Research
|
November 1, 1990
Phase I trial of escalating pentoxifylline dose with constant dose thiotepa
B J Dezube, J P Eder, A B Pardee
The Journal of Biological Chemistry
|
January 25, 1993
Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line
V T Chan, S W Ng, J P Eder, et al.
Cancer Research
|
January 15, 1991
A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity
J P Eder, C A Wheeler, B A Teicher, et al.
The Journal of Biological Chemistry
|
October 27, 1995
Molecular cloning and characterization of the promoter for the Chinese hamster DNA topoisomerase II alpha gene
S W Ng, J P Eder, L E Schnipper, et al.
The Journal of Biological Chemistry
|
July 5, 1993
Conditional expression of wild-type topoisomerase II complements a mutant enzyme in mammalian cells
J P Eder, V T Chan, E Niemierko, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
Influence of scheduling on two-drug combinations of alkylating agents in vivo
B A Teicher, S A Holden, S M Jones, et al.
Cancer Treatment Reports
|
July 1, 1986
Pharmacokinetics and immediate effects of high-dose carmustine in man
W D Henner, W P Peters, J P Eder, et al.
The Journal of Clinical Investigation
|
May 1, 1987
Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model
J P Eder, B A Teicher, S A Holden, et al.
Page
of 6